| R03AK07 |
Budesonide, Formoterol |
DuoResp® Spiromax® |
Inhalation powder |
160 mcg/4,5 mcg/dose - 120 doses |
UD |
1 |
Teva Pharma B.V., Нидерландия |
4 |
UD |
63.12 |
- |
1.56433 |
46.93 |
100% |
46.93 |
не се прилага на лица под 18 години |
J44.8,J45.0,J45.1 |
НСР-4735/02.10.2014; НСР-11068/01.12.2016; НСР-15141/02.03.2018; НСР-18990/13.06.2019 |
02.08.2019 |
|
|
Активен |
4016 |
| R03AK07 |
Budesonide, Formoterol |
SYMBICORT TURBUHALER |
Inhalation powder |
160 mcg/4,5 mcg/dose - 120 doses |
IU |
1 |
AstraZeneca AB, Швеция |
4 |
UD |
58.7 |
- |
1.56433 |
46.93 |
100% |
46.93 |
|
J44.8,J45.0,J45.1 |
№26/04.08.2009; №37/21,08,2009; КЦРР-925/04.07.2012 г.КЦРР-473/19.04.2012-КП-180/10.04.2013; НСР-2284/13.01.2014; НСР-4749/02.10.2014 и КП-21/17.02.2015.; НСР-9211/ 05.05.2016; КП-128/03.11.2017 и НСР-13509/18.08.2017; НСР-18105/07.03.2019 |
02.08.2019 |
08.09.2012 |
|
Активен |
3616 |
| R03AK07 |
Budesonide, Formoterol |
SYMBICORT TURBUHALER |
Inhalation powder |
320 mcg/9 mcg/dose - 60 doses |
IU |
1 |
AstraZeneca AB, Швеция |
2 |
UD |
60.04 |
- |
1.56433 |
46.93 |
100% |
46.93 |
|
J44.8,J45.0,J45.1 |
№26/04.08.2009; №37/21,08,2009; КЦРР-925/04.07.2012 г.; КЦРР-473/19.04.2012-КП-180/10.04.2013; НСР-2283/13.01.2014; НСР-4749/02.10.2014 и КП-17/17.02.2015.; НСР-9210/ 05.05.2016; КП-129/03.11.2017 и НСР-13510/18.08.2017; НСР-18106/07.03.2019 |
02.08.2019 |
08.09.2012 |
|
Активен |
3615 |
| R03AK07 |
Budesonide, Formoterol |
SYMBICORT TURBUHALER 160/4,5 MCG/INHALATION |
Inhalation powder |
160 mcg/4,5 mcg/dose - 60 doses |
IU |
1 |
AstraZeneca AB, Швеция |
4 |
UD |
48.6 |
- |
2.37233 |
35.58 |
100% |
35.58 |
|
J44.8,J45.0,J45.1 |
№26/04.08.2009; №37/21,08,2009; КЦРР-2774/20.03.2013 г.; НСР-6799/23.07.2015. |
16.08.2015 |
08.09.2012 |
|
Заличен |
1818 |
| R03AK07 |
Budesonide/Formoterol |
R03AK07 Budesonide/Formoterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AK07 |
Budesonide, Formoterol |
Symbicort |
Pressurised inhalation, suspension |
160 mcg/4,5 mcg - 120 actuations |
|
1 |
AstraZeneca AB, Швеция |
4 |
UD |
- |
68.6 |
2.28667 |
68.6 |
75% |
51.45 |
|
J44.8 |
НСР-11030/ 25.11.2016 (предварително изпълнение); НСР-13460/11.08.2017; НСР-15431/19.04.2018; НСР-19523/14.08.2019 |
02.09.2019 |
|
|
Активен |
15485 |
| R03AK08 |
Beclometasone dipropionate/ formoterol fumarate dihydrate |
R03AK08 Beclometasone dipropionate/ formoterol fumarate dihydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AK08 |
beclometasone, formoterol |
Foster |
Pressurised inhalation, solution |
0,1 mg/0,006 mg - 120 doses |
|
1 |
Chiesi Pharmaceuticals GmbH, Австрия |
4 |
UD |
65.78 |
- |
2.15867 |
64.76 |
100% |
64.76 |
|
J44.8,J45.0,J45.1 |
№ 33/21.08.2009; КЦРР-2924/20.03.2013 г; НСР-2384/21.01.2014; НСР-3867/20.06.2014; НСР-4746/02.10.2014; НСР-12738/19.05.2017; НСР-16269/27.07.2018 |
02.09.2019 |
08.09.2012 |
|
Активен |
3218 |
| R03AK08 |
beclometasone, formoterol |
Foster NEXThaler |
Inhalation powder |
100 mcg/6 mcg/dose - 120 doses |
|
1 |
Chiesi Pharmaceuticals GmbH, Австрия |
4 |
UD |
64.76 |
- |
2.15867 |
64.76 |
100% |
64.76 |
не се прилага на лица под 18 години |
J44.8,J45.0,J45.1 |
НСР-4734/02.10.2014.; НСР-6412/12.06.2015; НСР-8223/22.02.2016; НСР-10676/21.10.2016 и НСР-11029/25.11.2016 (предварително изпълнение); НСР-13278/20.07.2017; НСР-15354/30.03.2018; НСР-17355/30.11.2018; НСР-19456/07.08.2019 |
02.09.2019 |
|
|
Активен |
3217 |
| R03AK10 |
Fluticasone furoate/Vilanterol |
R03AK10 Fluticasone furoate/Vilanterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AK10 |
Fluticasone furoate, Vilanterol |
Relvar Ellipta |
Inhalation powder, pre dispensed |
184 mcg/22 mcg |
UD |
30 doses |
GlaxoSmithKline (Ireland) Limited, Ирландия |
1 |
UD |
71.76 |
- |
2.392 |
71.76 |
100% |
71.76 |
J45.0, J45.1- Не се прилага при лица, ненавършили 12 години |
J45.0,J45.1 |
НСР-4582/15.09.2014.; НСР-4697/26.09.2014.; НСР-6381/03.06.2015.; НСР-18241/22.03.2019; НСР-19272/18.07.2019 |
02.09.2019 |
|
|
Активен |
3176 |
| R03AK10 |
Fluticasone furoate, Vilanterol |
Relvar Ellipta |
Inhalation powder, pre dispensed |
92 mcg/22 mcg |
UD |
30 doses |
GlaxoSmithKline (Ireland) Limited, Ирландия |
1 |
UD |
61.37 |
- |
2.04567 |
61.37 |
100% |
61.37 |
J45.0, J45.1- Не се прилага при лица, ненавършили 12 години |
J44.8,J45.0,J45.1 |
НСР-4581/15.09.2014; НСР-6382/03.06.2015. и КП-360/26.08.2015.; НСР-9363/19.05.2016; НСР-13589/25.08.2017; НСР-15732/25.05.2018; НСР-18154/07.03.2019; НСР-19271/18.07.2019 |
02.09.2019 |
|
|
Активен |
3177 |
| R03AK11 |
Fluticasone propionate/formoterol fumarate dihydrate |
R03AK11 Fluticasone propionate/formoterol fumarate dihydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AK11 |
Fluticasone, Formoterol |
Flutiform |
Pressurised inhalation, suspension |
250 mcg/10 mcg (120 впръсквания) |
|
1 |
Mundipharma GmbH, Австрия |
2 |
UD |
108.28 |
- |
1.80467 |
108.28 |
100% |
108.28 |
Само при възрастни |
J45.0,J45.1 |
НСР-3169/07.04.2014.; НСР-5291/ 18.12.2014.; НСР-7183/09.10.2015.; КП-31/26.04.2018 и НСР-15070/23.02.2018; НСР-19671/29.08.2019 |
02.10.2019 |
|
|
Активен |
3457 |
| R03AK11 |
Fluticasone, Formoterol |
Flutiform |
Pressurised inhalation, suspension |
125 mcg/5 mcg (120 впръсквания) |
|
1 |
Mundipharma GmbH, Австрия |
4 |
UD |
66.8 |
- |
2.22667 |
66.8 |
100% |
66.8 |
При възрастни и деца над 12 години |
J45.0,J45.1 |
НСР-3169/07.04.2014.; НСР-5290/ 18.12.2014.; НСР-7184/09.10.2015.; КП-30/26.04.2018 и НСР-15071/23.02.2018; КП-41/25.04.2019 и НСР-17892/07.02.2019 |
02.06.2019 |
|
|
Активен |
3456 |
| R03AK11 |
Fluticasone, Formoterol |
Flutiform K-haler |
Pressurised inhalation, suspension |
125 mcg/5 mcg per actuation (120 впръсквания) |
|
1 |
Mundipharma GmbH, Австрия |
4 |
UD |
68.57 |
- |
2.22667 |
66.8 |
100% |
66.8 |
При възрастни и деца над 12 години |
J45.0,J45.1 |
НСР-15803/08.06.2018 |
02.06.2019 |
|
|
Активен |
16144 |
| R03AL03 |
Umeclidinium bromide/ Vilanterol |
R03AL03 Umeclidinium bromide/ Vilanterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AL03 |
Umeclidinium Bromide, Vilanterol |
ANORO ELLIPTA |
Inhalation powder, pre dispensed |
55 mcg/22 |
mcg |
1 inhaler (30 doses) |
GlaxoSmithKline (Ireland) Limited, Ирландия |
1 |
UD |
- |
102.6 |
3.42 |
102.6 |
75% |
76.95 |
|
J44.8 |
НСР-7453/10.11.2015.; НСР-9960/29.07.2016; НСР-12818/26.05.2017 г.; НСР-16690/30.08.2018; НСР-18473/22.04.2019 |
02.06.2019 |
|
|
Активен |
4097 |
| R03AL04 |
Indacaterol / Glycopyrronium bromide |
R03AL04 Indacaterol / Glycopyrronium bromide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AL04 |
Indacaterol and glycopyrronium bromide |
Ultibro Breezhaler |
Inhalation powder, hard capsule |
85 mcg /43 mcg |
|
30 x 1 capsules (unit dose) + 1 inhaler |
Novartis Europharm Limited, Ирландия |
1 |
UD (= 1 dose inhalation powder) |
- |
102.24 |
3.06324 |
91.9 |
75% |
68.92 |
|
J44.8 |
НСР-4636/15.09.2014; НСР-6138/29.04.2015.; НСР-11345/30.12.2016; Протокол 244/28.09.2017; НСР-14186/13.10.2017; НСР-15740/25.05.2018; НСР-16615/24.08.2018; НСР-17887/07.02.2019 |
02.04.2019 |
|
|
Активен |
3857 |
| R03AL05 |
Aclidinum bromide, Formoterol |
R03AL05 Aclidinum bromide, Formoterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AL05 |
Aclidinum bromide, Formoterol |
Brimica Genuair |
Inhalation powder |
340 mcg/12 mcg |
mcg |
1 inhaler with 60 actuations |
AstraZeneca AB, Швеция |
2 |
UD |
- |
102.95 |
3.43167 |
102.95 |
75% |
77.21 |
|
J44.8 |
НСР-14441/17.11.2017 |
02.01.2018 |
|
|
Активен |
15934 |
| R03AL05 |
Aclidinum bromide, Formoterol |
Duaklir Genuair |
Inhalation powder |
340 mcg/12 mcg |
mcg |
1 inhaler with 60 actuations |
AstraZeneca AB, Швеция |
2 |
UD |
- |
102.97 |
3.43167 |
102.95 |
75% |
77.21 |
|
J44.8 |
НСР-11253/16.12.2016 (допуска се предварително изпълнение); НСР-13783/12.09.2017 |
02.01.2018 |
|
|
Активен |
15519 |
| R03AL06 |
Tiotropium bromide, Olodaterol |
R03AL06 Tiotropium bromide, Olodaterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| R03AL06 |
Tiotropium bromide, Olodaterol |
Spiolto Respimat |
Inhalation solution |
2,5 mcg/2,5 mcg |
|
Single pack: 1 cartridge, providing 60 puffs (30 medicinal doses) |
Boehringer Ingelheim International GmbH, Германия |
2 |
UD |
- |
92.76 |
3.092 |
92.76 |
75% |
69.57 |
|
J44.8 |
НСР-19823/20.09.2019 - Предварително изпълнение |
02.10.2019 |
|
|
Активен |
16702 |